Century Therapeutics and Bristol Myers Squibb (BMS) are collaborating on four programs for hematologic malignancies and tumors.
BMS, which has a presence in Seattle, will be responsible for clinical development and commercialization of development candidates as a part of the deal while Century will generate development candidates and preclinical development activities for each program.
“We are pleased to partner with Bristol Myers Squibb, a global leader in oncology and hematology, to further expand our pipeline of iPSC-derived cell therapy products for challenging hematological and solid tumor malignancies,” said Osvaldo Flores, Ph.D., CEO of Century Therapeutics.